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OVERVIEW 
Comprehensive medication management (CMM) is an important tool to address medication-related morbidity and mortality and 
reduce health care costs. Medication therapy problems (MTPs) are a significant and costly barrier to improving patient outcomes1 and 
with more than half of all Americans taking at least one prescription drug,2 the need to manage and optimize patients’ medications is 
greater than ever.  
 
This report examines select practice and practitioner characteristics of the primary care clinics that participated in the research project, 
Enhancing Performance in Primary Care Medical Practice through Implementation of Comprehensive Medication Management. To be 
eligible to participate, sites had to have: established relationships with care team providers, a way of electronically identifying patients 
most in need of CMM, reporting processes in place for CMM data, read/write access in the electronic medical record, and an 
established CMM practice or a commitment to providing CMM. Because of these inclusion criteria, most participating clinics had CMM 
services in place for several years and were mature in their design and delivery of services.  
 
Site characteristics around the following areas were assessed: pharmacist and clinic demographics, delivery of pharmacy services, 
collaboration, billing and payment for CMM, and measuring CMM outcomes. The results of this report shed light on how CMM is being 
delivered in a sample of established CMM practices and therefore may provide benefit to those practitioners interested in building 
their own CMM practice.  
 
BACKGROUND 
A growing concern in health care in the United States is the rising costs attributed to prescription drug use. In 2015, prescription drug 
spending accounted for 10.1% of the $3.2 trillion spent on total national health expenditures.3 In 2018, it was reported that health 
care costs caused by improper and unnecessary use of medicines exceed $500 billion per year.1 Correcting this issue and optimizing 
medication use is critical to help our country improve health care at lower costs.  
  
As our health care system expands adoption of compensation systems rooted in demonstration of value, it is of utmost importance 
that pharmacy leaders define and share the value of comprehensive medication management (CMM) services as a key component of 
team-based care. Clinical pharmacists are best equipped to work collaboratively with other health care providers to improve 
medication use through the provision of CMM.4,5  
 
CMM is the practice of individualized patient care to ensure that each medication a patient is taking is appropriate, effective for the 
indicated condition, safe for the patient, and able to be taken by the patient as intended.6,7 CMM involves the assessment of a patient 
and development of an individualized care plan to achieve the intended goals of therapy with appropriate follow-up to determine 
patient outcomes.6,7 CMM includes a follow-up evaluation to ensure the patient is meeting their goals for their medication therapy. A 
requirement of CMM is collaboration among the various members of the health care team.8 Many primary care clinics offer this service, 
but it is unclear how closely providers adhere to this definition of CMM.  
 
The literature has discussed the need for a consistent pharmacist patient care process (PPCP).9-12 The landmark model proposed by 
the Joint Commission of Pharmacy Practitioners outlined the recommended PPCP that pharmacists should adhere to in caring for 
patients.11 This work was significant because of the endorsement by multiple pharmacy organizations. While there is now general 
agreement on the elements of the PPCP, no known literature exists examining how closely pharmacists are following the PPCP in 
practice.  
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The CMM Primary Care Study 
This work was supported by the grant Enhancing Performance in Primary Care Medical Practice through Implementation of 
Comprehensive Medication Management funded by the American College of Clinical Pharmacy (ACCP) and the ACCP Foundation. The 
project was led by the University of North Carolina Eshelman School of Pharmacy, the University of Minnesota College of Pharmacy, 
the American Academy of Family Physicians (AAFP) National Research Network, and the Alliance for Integrated Medication 
Management (AIMM). The aims of the research were: 
 
AIM 1: Assess baseline demographics, state of CMM within each practice, and practitioner and organizational readiness and 
capacity for CMM service development, refinement, and expansion. 
AIM 2: Determine best practices in the design and delivery of CMM in primary care that optimize medication use (i.e., how CMM 
is best delivered to patients in primary care). 
AIM 3: Determine the structural and system-level elements (i.e., the practice management system) that are needed to support the 
effective and efficient delivery of CMM and establish initial benchmarks for practice quality and efficiency. 
AIM 4: Determine the key performance measures that support the value proposition for CMM from the perspective of stakeholders 
internal and external to the providing organization, and evaluate performance of study sites individually and collectively according 
to these key measures. 
AIM 5: Accelerate the adoption of CMM best practices through (a) replication across the study sites; (b) dissemination across a 
facilitated community of learning to primary care 
 
Study activities were carried out between January 2016 and June 2018.  
 
Identifying the Study Sites 
Per the expectations set by the funder via the original request for proposal announcement, sites included in the study were required 
to have well-established CMM services delivered by pharmacists embedded in the primary care clinic and acknowledge that they were 
offering CMM, as defined in the ACCP Standards of Practice for Clinical Pharmacists4 and the Patient-Centered Primary Care 
Collaborative Comprehensive Medication Management Resource Guide.7 These documents outline steps to provide CMM as well as 
the expectations for clinical pharmacists delivering the service. Participating clinics were recruited by the University of Minnesota, the 
University of North Carolina, and the AAFP National Research Network. The University of Minnesota and the University of North 
Carolina both recruited a diverse group of primary care sites with which they had existing relationships. AAFP put out a national call 
to members of the AAFP National Research Network to participate in the study and those who responded and met the inclusion criteria 
were included in the study. To meet the minimum eligibility requirements, all sites needed to: 
 
• Be part of existing primary care medical practices  
• Represent a diversity of primary care sites (e.g., community-based health centers, safety net clinics, independent primary 
care clinics) 
• Have established team-based relationships where clinical pharmacists are authorized by collaborative practice agreements 
(CPAs) and/or by a documented privileging process to engage in patient encounters 
• Have an electronic patient registry or a means of identifying patients most in need of CMM 
• Have read/write access for the clinical pharmacists in the electronic medical records (EMR) 
• Have an existing approach to reporting quality measures on a regular basis for practice improvement (e.g., hospitalizations, 
emergency department visits, clinical care gaps, clinic revenue) 
• Provide or have the commitment to provide CMM services in accordance with ACCP standards4 regarding care process and 
documentation and in the context of team-based care delivery 
 
Aims of this Report 
The purpose of this report is to present the findings of Aim 1 where the baseline demographics and the state of CMM within each 
practice were assessed. Pharmacy practitioners and administrators frequently seek guidance on building CMM practices and 
understanding of how other sites are delivering CMM services. This is evidenced by the frequent inquiries for this type of information 
posted on professional listservs such as the American College of Clinical Pharmacy (ACCP) Ambulatory Care PRN, American Society of 
Health-System Pharmacists (ASHP) Connect, American Pharmacists Association (APhA) ENGAGE, among others. Therefore, this report 
was created to: 
1. Provide a snapshot of CMM practice among a sample of mature primary care clinics currently delivering CMM. 
2. Describe the baseline status of CMM service delivery across sites enrolled in the Enhancing Performance in Primary Care 
Medical Practice through Implementation of Comprehensive Medication Management study. 
3. Provide an overview for those practitioners interested in building a CMM practice to guide care delivery and practice 
management. 
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METHODS 
Survey Design 
Two separate surveys were administered: a demographics survey and baseline survey. The demographics survey addressed both 
pharmacist-level and practice-level demographic questions. The demographics survey consisted of 70 questions; however, response 
logic limited the total number of questions for individual participants.  
 
The baseline survey addressed seven domains: clinic demographics, pharmacy services, clinic resources for providing CMM, measuring 
outcomes and quality assurance related to CMM, the pharmacy team, creating a shared vision around CMM, and collaboration within 
the clinic. These domains were chosen based on the content expertise of the research team, as well as a review of resources previously 
shared via professional societies and other publicly available reports.4,13-18 The baseline survey was 80 questions. 
 
Both the demographic and baseline survey were reviewed by a survey research consultant at the University of North Carolina who 
provided feedback and suggestions for improvement on survey structure and items. The baseline survey was pilot tested by four 
clinical pharmacists practicing in ambulatory care settings May – June 2016. The purpose of the pilot was to gain feedback on the 
terminology used throughout the survey, ensure that the items were clear and could be answered by participants, as well as to provide 
any overall feedback on the survey. The survey questions were modified based on pilot tester feedback.  
 
Both the demographic and baseline surveys were built into Qualtrics (Qualtrics, Provo, UT) and administered via email to the lead 
pharmacist of all participating clinics in August 2016. Participants were asked to complete the surveys within two weeks, and were 
sent up to three reminders, if necessary.  
 
Two clinics were added to the study in October 2016 and sent the baseline and demographic surveys at that time. In total, 40 clinics 
completed the CMM demographic and baseline surveys. Results were analyzed descriptively in Microsoft Excel. 
 
RESULTS 
Pharmacist and Clinic Demographics 
Table 1 presents relevant demographic information of the lead pharmacists from each of the participating clinics. Most pharmacists 
had a Doctor of Pharmacy degree, had completed a pharmacy residency, and had obtained at least one board of pharmacy 
certification.  
 
Table 1. Demographics of lead pharmacist (n=40) at participating sites 
Characteristic N (%) 
Pharmacy degree(s)  
PharmD 36 (90%) 
BS Pharm and PharmD 4 (10%) 
Additional post-graduate training completed   
PGY1 33 (82.5%) 
PGY2 5 (12.5%) 
Fellowship 1 (2.5%) 
MBA 1 (2.5%) 
MS 1 (2.5%) 
Board of pharmacy certification  
Ambulatory care 16 (40%) 
Pharmacotherapy 9 (22.5%) 
Ambulatory care and Pharmacotherapy 3 (7.5%) 
 
 
Table 2 illustrates some of the characteristics of the clinics in the study. Most clinics were in Minnesota and were part of a patient-
centered medical home (PCMH). While most clinics had CMM programs that had been established for several years, many clinics did 
not have a pharmacist present five days a week, or one full time equivalent (FTE). Many clinics were teaching clinics and had PharmD 
students in their practice completing rotations, as well as pharmacy residents which increased the number of pharmacists providing 
CMM on their team.  
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Table 2. Demographics of participating clinics (n=40) 
Characteristic N (%) 
Practice location  
Minnesota 25 (62.5%) 
North Carolina 10 (25%) 
New Mexico 1 (2.5%) 
New York 3 (7.5%) 
Wisconsin 1 (2.5%) 
Clinic is a certified patient-centered medical home (n = 39)  
Yes 32 (82%) 
No 7 (18%) 
Pharmacist FTEs dedicated to clinic, mean ± SD 0.68 ± 0.52 
Year CMM was first established at practice (n = 39), mean ± SD 2009 ± 5 
Have P1-P3 students at practice 8 (20%) 
Have 4th year PharmD students completing Advanced Pharmacy Practice 
Experiences (APPEs)  
34 (85%) 
Have PGY1 or PGY2 pharmacy residents 22 (55%) 
More than one pharmacist practicing on CMM team (n=39) 24 (61.5%) 
 
Delivery of Pharmacy Services 
Table 3 illustrates how CMM visits were conducted in study sites. Two-thirds of sites were using health information technology to 
prospectively identify CMM patients, but fewer than half of sites had formal criteria that they utilized to identify patients for CMM. 
Initial CMM visits were typically scheduled for around one hour, while most sites scheduled follow-up visits for a half-hour. Most 
practices facilitated CMM referrals by including a process for electronic referral in the EMR. There was a lack of standardization of 
some aspects of the visit. For example, not all sites reported having a systematic process in place for categorizing MTP, or a standard 
way to document CMM visits. In addition, only half of the study sites had processes in place to assure quality of CMM services. Most 
sites had a written mission or vision for their CMM program, but not a written business plan or strategic plan. Finally, most sites applied 
a credentialing process for their pharmacists who provide CMM, but not a privileging process.  
 
Table 3. CMM Service Characteristics (n=40) 
Characteristic N (%) 
Approximate number of CMM visits at clinic within a week per FTE, mean ± SD 21.7 ± 15.6 
Clinic utilizes health information technology (e.g., EMR-generated lists of high risk patients, risk 
stratification algorithms) to prospectively identify populations of patients who would benefit most 
from CMM services (n=39) 
26 (66.7%) 
Formal criteria are in place (e.g., specific conditions, number of medications) that guide the 
identification of patients most in need of CMM to then target patients for CMM services 
18 (45%) 
Number of minutes initial CMM visits are typically scheduled, mean ± SD  49 ± 15.2 
Number of minutes follow-up CMM visits are typically scheduled, mean ± SD 27.6 ± 5.3 
A process is in place that allows for electronic referral of patients from clinicians to pharmacists for 
CMM services 
35 (87.5%) 
A systematic process for categorizing medication-related problems/drug therapy problems is 
employed 
29 (72.5%) 
Always document in the electronic medical record a care plan (e.g., a SOAP note or related encounter 
note) for each CMM visit 
39 (97.5%) 
CMM visits are documented in a medical record that is accessible by other clinicians/providers within 
the clinic 
40 (100%) 
The clinic has a standard format/template for recording CMM visits in the medical chart 35 (87.5%) 
A process is in place to assure the quality of CMM services delivered by pharmacists  
Yes 20 (50%) 
Somewhat 8 (20%) 
No 12 (30%) 
Pharmacists lead or participate in medication-focused quality improvement initiatives 24 (60%) 
Have a written business plan or strategic plan for CMM program to support establishment of 
sustainability within the organization (n = 31) 
 
Yes 11 (35.5%) 
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Somewhat 6 (19.4%) 
No 14 (45.2%) 
A credentialing process for pharmacists who provide CMM is applied 28 (70%) 
A privileging process for pharmacists who provide CMM is applied (n = 33) 14 (42.4%) 
Have a written mission and/or vision statement for your CMM practice separate from your clinic 
mission/vision statement 
26 (65%) 
 
 
Table 4 illustrates that there was considerable variation in applying the PPCP. For example, about a quarter of sites reported not always 
assessing all medications a patient is taking. In addition, many other steps of the patient care process are not always followed, including 
assessing the indication, effectiveness, safety, and adherence of every medication. 
 
Table 4. Incorporation of various aspects of the CMM patient care process into CMM visits (n=40) 
Throughout the course of working with a CMM patient (whether initial 
or follow-up) the following are assessed: 
Always Sometimes Never 
The patient’s medication experience (e.g., attitudes, beliefs, concerns, 
and expectations of medication) recorded in the medical chart 
12 (30%) 28 (70%) 0 (0%) 
All medications the patient is taking (including prescription, 
nonprescription, herbal, vitamins, and supplements)  
31 (77.5%) 9 (22.5%) 0 (0%) 
The indication of every medication a patient is taking  31 (77.5%) 9 (22.5%) 0 (0%) 
If the patient needs any medication(s) for a condition that is 
NOT currently being treated or prevented  
26 (65%) 13 (32.5%) 1 (2.5%) 
The effectiveness of every medication a patient is taking  24 (60%) 16 (40%) 0 (0%) 
Side effects and/or adverse reactions of every medication a patient is 
taking (n = 39) 
25 (64.1%) 14 (35.9%) 0 (0%) 
A patient’s adherence to every medication  27 (67.5%) 13 (32.5%) 0 (0%) 
Document individualized goals of therapy for each condition/medication 
during a CMM encounter 
22 (55%) 17 (42.5%) 1 (2.5%) 
 
 
Collaboration 
Table 5 demonstrates that most pharmacists in the study have developed CPAs for a variety of common conditions. 
 
Table 5. Existing collaborative practice agreements (CPAs) (n=40) 
Collaborative practice agreements (CPA)  
exist for the following conditions:  
N (%) 
Anticoagulation 12 (30%) 
Asthma 18 (45%) 
COPD 16 (40%) 
Depression 12 (30%) 
Diabetes 27 (67.5%) 
Dyslipidemia 23 (57.5%) 
Flu/antiviral 3 (7.5%) 
GERD 11 (27.5%) 
Hypertension 29 (72.5%)  
Hypothyroidism 19 (47.5%) 
Pain 15 (37.5%) 
Tobacco cessation 26 (65%) 
Currently no CPAs are in place 6 (15%) 
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Pharmacists at these sites were utilizing support staff for a variety of CMM-related tasks. Table 6 shows that over half of all pharmacists 
use support staff for triaging phone calls, scheduling CMM visits, and billing for CMM services.  
 
Table 6. Components of the CMM visit that pharmacists utilize support staff (n=40) 
Utilize support staff for:  N (%) 
Scheduling 39 (97.5%) 
Triaging phone calls 27 (67.5%) 
Billing 22 (55%) 
Performing point-of-care testing 16 (40%) 
Enrolling patients in patient assistance programs 13 (32.5%) 
Rooming patients 13 (32.5%) 
Conducting follow-up phone calls 10 (25%) 
Clinic staff do not support any of the above activities 1 (2.5%) 
 
Table 7 describes the members of the care team pharmacists collaborate with and the level of collaboration they feel they have.  
 
Table 7. Team members in the clinic the pharmacist collaborates with when providing CMM (n=40) 
Collaborator  N (%) 
Physicians 40 (100%) 
Other pharmacists 32 (80%) 
Care managers 31 (77.5%) 
Nurse practitioners 31 (77.5%) 
Social workers 27 (67.5%) 
Mental health 26 (65%) 
Physician assistants 26 (65%) 
Dieticians 16 (40%) 
Pharmacy technicians 12 (30%) 
Physical therapists 4 (10%) 
The level of collaboration between pharmacists and other 
members of the health care team in clinic regarding CMM 
 
Excellent 22 (55%) 
Good 17 (42.5%) 
Fair 1 (2.5%) 
Poor 0 (0%) 
Very poor 0 (0%) 
 
Practice Management 
Billing and Payment for CMM 
CMM programs engage in many different approaches to bill and obtain revenue, as demonstrated in Table 8. While most pharmacists 
bill third party payers for CMM services, only about a third of CMM patient visits actually result in payment.  
 
Table 8. CMM financial characteristics of participating clinics (n=40) 
Characteristic N (%) 
Payer mix of clinic overall by percentage*  
Medicare, mean ± SD 23.2% ± 18.2 
Medicaid, mean ± SD 25.5% ± 19.5 
Dual eligible, mean ± SD 7.65% ± 13.7 
Commercial (i.e., third party payer), mean ± SD 37.6% ± 23 
Uninsured/Self-pay, mean ± SD 4.1% ± 6.7 
Other, mean ± SD 2% ± 5.9 
Payer mix of patients receiving CMM by percentage*  
Medicare, mean ± SD 40.7% ± 30.0 
Medicaid, mean ± SD 18.9% ± 22.8 
Dual eligible, mean ± SD 8.4% ± 14.6 
Commercial (i.e., third party payer), mean ± SD 27.4% ± 26.0 
Uninsured/Self-pay, mean ± SD 2.9% ± 7.4 
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                          2019, Vol. 10, No. 1, Article 5                      INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i1.1611 
7 
 
Other, mean ± SD 1.7% ± 5.3 
Source of funding for providing CMM  
Primary care medical practice 5 (12.5%) 
The health care organization (e.g., health system, clinically integrated network) 27 (67.5%) 
School or College of Pharmacy 9 (22.5%) 
Partnering entity 1 (2.5%) 
Other 3 (7.5%) 
Billing third party payers for pharmacist services for pharmacist-provided patient care 
services 
34 (85%) 
Percent of CMM patients for whom pharmacists receive payment (n=32), mean ± SD 33.83% ± 33.28 
Requirement that pharmacists have specific credentials or training beyond their pharmacy 
degree by payers to whom pharmacists submit claims to provide payment (n = 32) 
8 (25%) 
*Combination of actual and respondent-estimated data 
 
Measuring CMM Outcomes 
Table 9 outlines the various measures that pharmacists indicated they are applying to CMM.  
 
Table 9. Collected Measures Related to CMM (n=40) 
Measures Related to CMM N (%) 
Number of medication-related problems identified 30 (75%) 
Number of medication-related problems resolved 27 (67.5%) 
Patient satisfaction 26 (65%) 
Patients meeting clinical goals (e.g., number of patients reaching hypertension, 
diabetes goals) compared to baseline 
22 (55%) 
Clinician satisfaction  14 (35%) 
Reduction in hospital readmissions 12 (30%) 
Achievement of pay-for-performance measures 8 (20%) 
Total cost of care savings 7 (17.5%) 
Reduction in hospital admissions 5 (12.5%) 
Impact on medical providers (e.g., satisfaction, relative value units) 5 (12.5%) 
Return on investment 5 (12.5%) 
Medication cost impact (whether savings or increases in cost attributed to 
medications) 
4 (10%) 
Change in medication adherence 4 (10%) 
Medication errors 3 (7.5%) 
Reduction in emergency room visits 2 (5%) 
Reduction in number of clinician visits 1 (2.5%) 
Change in ambulatory care resource utilization for defined groups of patients (e.g., 
walk-in appointment requests, phone calls to triage) 
0 (0%) 
Our clinical/practice tracks clinical/financial goals, but we do not separate these out 
for patients receiving our CMM services versus others not receiving our services 
14 (35%) 
I/we are not tracking any measures to describe CMM impact in this clinic. 2 (5%) 
 
 
Pharmacists collect data from a variety of sources. While most can use data from the EMR, almost half still rely on manual tracking 
data, as shown in Table 10.  
Table 10. Collection of CMM data (n=40) 
Source of data used to support outcomes  
assessment associated with CMM services  
N (%) 
Electronic medical record 35 (87.5%) 
Surveys 23 (57.5%) 
Manual tracking 18 (45%) 
Pharmacy claims data 6 (15%) 
Medical claims data 6 (15%) 
Do not currently collect any outcomes 3 (7.5%) 
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KEY FINDINGS AND IMPLICATIONS 
The primary care pharmacists and sites highlighted in this report represent the characteristics of high performing CMM practices in a 
variety of settings. These data illustrate how CMM is being delivered in primary care and shed light on areas of inconsistency and 
opportunities for growth, as well as advancements that have been made in terms of CMM delivery, integration, and sustainability. 
Moving forward, there are a number of key points to consider when delivering CMM.  
 
• Most sites do not have a full-time equivalent pharmacist.  
o Implications: Part-time presence of a CMM pharmacist can be effective in balancing fiscal restraints and building 
sustainability. However, it may also limit the degree to which CMM can fully reach a population of need. 
• Most sites schedule initial CMM visits for 60 minutes and follow-up visits for 30 minutes.  
o Implications: While many visits with primary care providers are scheduled for 20 minutes, to perform a 
comprehensive assessment and create a care plan for a CMM patient requires significantly more time, both in the 
initial visit and during subsequent follow-up visits.   
• Many clinics do not use formal criteria for identifying patients most in need of CMM.  
o Implications: Without standard criteria for identifying patients most in need of CMM, there may be inconsistency in 
how patients are identified by both pharmacists and other health care providers. Identifying populations that would 
benefit from CMM may lead to enhanced value of CMM.  
• Most practices have facilitated CMM referrals by including a process for electronic referral in the EMR. 
o Implications: Electronic referral for CMM patients streamlines the process and fits in with referrals for other services, 
which may therefore lead to increased uptake of CMM.  
• Over half of all study sites use support staff to assist in triaging CMM phone calls, scheduling CMM visits, and billing. 
o Implications: Support staff can reduce time spent on administrative tasks, thus freeing up more time for pharmacists 
to provide CMM. However, there are several additional areas where support staff could be maximized, such as 
rooming patients and assisting with follow-up. 
• Not all sites have adopted a consistent taxonomy for categorizing MTPs or a systematic process for documenting and 
monitoring resolution of MTPs. 
o Implications: Using a standardized approach for categorizing medication therapy problems is a key component of 
producing fidelity in the care process for CMM. It can help patients, providers, and other pharmacists better 
understand the PPCP. It can also support consistent delivery of care across pharmacists and help produce consistent 
outcomes from CMM services. 
• Half of the study sites have adopted a process to assure the quality of CMM services delivered by pharmacists. 
o Implications: Quality assurance is important to ensure standardization and quality of CMM. The experience of sites 
that have invested in the development of quality assurance systems for CMM can serve as models for the profession. 
The profession should also consider ways to support quality assurance in organizations where the number of 
practitioners committed to CMM service delivery may not effectively allow internally-based quality assurance 
systems.  
• Pharmacists are not always consistently incorporating certain steps of the PPCP in their visits, such as evaluating indication, 
effectiveness, safety, and adherence of every medication.  
o Implications: Consistently delivering CMM is of utmost importance. A consistent service needs to be delivered to 
ensure fidelity, achieve quality outcomes, and demonstrate the value of CMM across settings.   
• Many sites are sustainably performing CMM services despite limited or even absent direct revenue from these services. 
o Implications: As value-based payment systems grow, there is evidence that the impact of CMM on quality, cost, or 
other factors is as important, or possibly more important, than ensuring a revenue stream that fully supports CMM 
services. Those who are seeking to implement CMM should focus on a multi-faceted approach to establishing the 
business case for CMM services.   
• Most pharmacists participating in this study were employed and funded directly by the host organization. 
o Implications: While many clinical positions for pharmacists in primary care initially were established through 
academic partnerships through which the academic institution provided all or most of the salary support, the sites 
in this study have demonstrated that a value proposition can be established that justifies full funding for CMM 
services through a health care organization. 
 
Practitioners building CMM practices frequently seek guidance on various aspects of service delivery, such as CPAs, billing, and quality 
assurance. This report provides an overview for those practitioners interested in building a CMM practice to guide care delivery and 
practice management, as well as those practitioners already providing CMM who wish to compare their practice to the sites involved 
in this cohort of mature CMM practices.  
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